Human Molecular Genetics Advance Access published online on July 13, 2005
Human Molecular Genetics, doi:10.1093/hmg/ddi246
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Clinical Cancer Genetics Program, Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA; Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH, USA
* To whom correspondence should be addressed. PTEN, encoding a dual phosphatase tumor suppressor, is mutated in 85% and 65% of individuals with Cowden Syndrome (CS) and Bannayan-Riley-Ruvalcaba syndrome (BRRS), respectively. Approximately 23 germline mutations in putative splice-sites have been published, but resulting downstream outcome data are limited. We determined splicing defects in PTEN in 40 germline PTEN mutation positive and 33 mutation negative cases with classic CS, BRRS and CS- or BRRS-like features. Altered splicing was observed in 4/40 mutation positive probands and 2/33 mutation negative probands. We then sought to characterize the transcriptional and biochemical outcome of the 5 distinct splice-site mutations, which led to the skipping of exon 3, 4 or 6. Two mutation negative BRRS patients also showed exon 3 skipping, and later, genomic sequencing revealed a mutation deep in intron 2. The splice-site mutations leading to deletions of exon 3, 4 or 6 resulted in reduced dual phosphatase activities of PTEN. Deletion of exon 4 was associated with severely reduced lipid phosphatase activity, whereas exon 3 skipping resulted in markedly reduced protein phosphatase activity. Furthermore, exon 3 deleted transcript and protein were stable and localized to the nucleus more efficiently than the wild-type PTEN. In contrast, exon 4 skipping resulted in unstable transcripts and severely truncated unstable PTEN protein lacking its phosphatase domain. We have not only described for the first time, the effect of a deep intronic/branch site mutation on exon skipping in PTEN, but also found that different splice-site mutations resulting in deletion of different exons lead to distinct outcomes.
Received May 17, 2005
Revised July 5, 2005
Accepted July 5, 2005
Article
Different splicing defects lead to differential effects downstream of the lipid and protein phosphatase activities of PTEN
2 Clinical Cancer Genetics Program, Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA; Division of Human Genetics, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
3 Clinical Cancer Genetics Program, Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA; Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH, USA; Division of Human Genetics, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA; Genomic Medicine Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic Foundation and Department of Genetics, Case Western Reserve University, 9500 Euclid Avenue, #NE-40, Cleveland, OH 44195, USA; Cancer Research UK Human Cancer Genetics Research Group, University of Cambridge, Cambridge, UK
Charis Eng, E-mail: engc{at}ccf.org or spsmce@netscape.net
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Korner and L. J. Miller Alternative Splicing of Pre-mRNA in Cancer: Focus on G Protein-Coupled Peptide Hormone Receptors Am. J. Pathol., August 1, 2009; 175(2): 461 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ghosh, H. Kuppusamy, and L. M. Pilarski Aberrant Splice Variants of HAS1 (Hyaluronan Synthase 1) Multimerize with and Modulate Normally Spliced HAS1 Protein: A POTENTIAL MECHANISM PROMOTING HUMAN CANCER J. Biol. Chem., July 10, 2009; 284(28): 18840 - 18850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Adamia, A. A. Reichert, H. Kuppusamy, J. Kriangkum, A. Ghosh, J. J. Hodges, P. M. Pilarski, S. P. Treon, M. J. Mant, T. Reiman, et al. Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia Blood, December 15, 2008; 112(13): 5111 - 5121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tamguney and D. Stokoe New insights into PTEN J. Cell Sci., December 1, 2007; 120(23): 4071 - 4079. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Agrawal and C. Eng Differential expression of novel naturally occurring splice variants of PTEN and their functional consequences in Cowden syndrome and sporadic breast cancer Hum. Mol. Genet., March 1, 2006; 15(5): 777 - 787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Weber and C. Eng Editorial: Germline Variants within RET: Clinical Utility or Scientific Playtoy? J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6334 - 6336. [Full Text] [PDF]
|
|